Navigation Links
/CORRECTION//- RxElite Temporarily Suspends Sales Under Its Registration Statement
Date:1/8/2008

MERIDIAN, Idaho, Jan. 8 /PRNewswire-FirstCall/ -- RxElite, Inc. (OTC Bulletin Board: RXEI), a developer, manufacturer, and marketer of specialty generic prescription drug products, announced today that as permitted under the registration rights agreement, it has voluntarily instructed all named selling stockholders to cease using the company's Registration Statement on Form SB-2 (File No. 333-146641) and January 3, 2008 prospectus until further advised. This release corrects and should replace the release of January 4, 2008 in its entirety. Once conditions permit reliance on the prospectus included in the Registration Statement, the company will notify selling stockholders.

This notice is provided for informational purposes only, and does not represent a solicitation or offer to buy or sell any security. Any offer will be made my means of a current prospectus only. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sales of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About RxElite, Inc.

RxElite, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), and transdermal patch products.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause our actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not limited to: risks associated with the uncertainty of future financial results, our reliance on our sole supplier, the limited diversification of our product offerings, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.

Contacts:

Corporate Information Investor Relations

Ph: (208) 288-5550 Charlie Forshee, 215-885-4981

Toll Free: (800) 414-1901 investorrelations@rxelite.com

Fax: (208) 288-1191 Segue Ventures LLC


'/>"/>
SOURCE RxElite, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
2. Surgical and Trauma Wound Care Market to Tie Up $7 Billion in Sales by 2011
3. ForceLogix, Innovex Win Sales Operational Performance Award
4. Southern Research Expands Sales and Marketing Agreement with Absorption Systems to Service European Market
5. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
6. Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin
7. Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54.
8. OmniSonics Appoints Sean McNerney as Vice President, Sales
9. SPO Medical Announces Major Sales Milestone
10. Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011
11. Stallergenes : 3rd Quarter Sales Up 17%: 9- Month Cumulative Sales Up 17%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, doctors ... being treated for breast cancer benefitted from an injection of stem cells derived from ... frequent side effect of cancer treatment. , Lymphedema refers to the swelling ...
(Date:6/23/2016)... , June 23, 2016 On Wednesday, ... at 4,833.32, down 0.22%; the Dow Jones Industrial Average edged ... closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on ... ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals ... (NASDAQ: BIND ). Learn more about these stocks ...
(Date:6/23/2016)... , June 22, 2016  Amgen (NASDAQ: ... of the QB3@953 life sciences incubator to ... health. The shared laboratory space at QB3@953 was created ... a key obstacle for many early stage organizations - ... of the sponsorship, Amgen launched two "Amgen Golden Ticket" ...
Breaking Biology Technology:
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):